Navigation Links
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
Date:1/7/2008

uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending September 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R) is a registered trademark of Genzyme Corporation. All rights reserved.

Isis Safe Harbor Statement

This release includes forward-looking statements regarding Isis' strategic alliance with Genzyme Corp., the development and commercialization potential of mipomersen for cardiovascular disease, and Isis' research and development opportunities in disease areas including CNS and certain rare diseases. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on fact
'/>"/>

SOURCE Genzyme Corp.; Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
2. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
3. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
4. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
5. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
6. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
7. Genzyme Launches Cholestagel(R) in Europe
8. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
9. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
10. Genzyme Recognized by Scientists as a Top Employer
11. Genzyme Receives Approval to Market Elaprase(R) in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... inVentiv Health, Inc., offering best-in-class clinical, commercial ... today that it has been selected by the ... operations support, as well as recruiting and sales ... for Type 2 diabetes. inVentiv ...
... Amex: CUR ) announced that the ongoing Phase ... amyotrophic lateral sclerosis (ALS or Lou Gehrig,s disease) was featured ... (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO) The trial was ... About Neuralstem ...
... 2011 VIVUS, Inc. (NASDAQ: VVUS ) ... 3 long-term safety and efficacy study of the investigational ... was presented over the weekend at the 2011 Sexual ... Vegas, NV.  Andrew R. McCullough, MD, Professor of Surgery/Urology ...
Cached Biology Technology:inVentiv Health Selected to Provide Sales Operations Support for Santarus 2inVentiv Health Selected to Provide Sales Operations Support for Santarus 3inVentiv Health Selected to Provide Sales Operations Support for Santarus 4Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta 215-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 215-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 315-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 4
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research and ... addition of the "Micro Market Monitor: North America ... http://photos.prnewswire.com/prnh/20130307/600769 ... grow at a CAGR of 3.6% from 2014 to ... in this market, Canada is ...
(Date:12/17/2014)... FORT BELVOIR, Va. , Dec. 15, 2014 ... its efforts to make it easier to detect ... supply chain. Today the agency started ... marking. The capability will validate the authenticity of ... supply chain. The new quality control measures will ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... A once-a-day, short-term treatment with a drug compound substantially ... symptoms, say researchers at the Stanford University School of ... gains lasted for months after the treatment was discontinued. ... test whether the compound has a similar effect in ...
... tough job. Yet, our bones undergo remodeling every day of ... new bone can form. In diseases such as osteoporosis, an ... loss. New research at the Weizmann Institute of Science, which ... in unprecedented detail how the roving cells whose job is ...
... slowly ebbing due to degenerative diseases of the eye, the ... , In a study in rats, neural progenitor cells derived ... the vision of animals with degenerative eye disease similar to ... appears today (March 28) in the journal Public Library of ...
Cached Biology News:Drug treatment improves learning in mice with Down syndrome symptoms, Stanford/Packard study shows 2Drug treatment improves learning in mice with Down syndrome symptoms, Stanford/Packard study shows 3Drug treatment improves learning in mice with Down syndrome symptoms, Stanford/Packard study shows 4Ring-around-the-cell 2Stem cell therapy shows promise for rescuing deteriorating vision 2Stem cell therapy shows promise for rescuing deteriorating vision 3
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
JAB1 Immunogen: Synthetic peptide, conjugated to KLH, corresponding to residues S(201) E Y Q T I P L N K I E D F G V(216) of human JAB1. The sequence is identical in mouse and rat. Storage: -...
Hamartin/TSC1 (1B2) Mouse mAb Ship: Hot Store: -20 C...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
Biology Products: